Development and commercialization of own supergeneric drug products represent a significant business opportunity. DelSiTech is open for discussion with industry partners as well as with financing organizations.
DelSiTech intends to develop in-house products until the preliminary proof-of-concept has been shown in clinical studies with patients. This is followed by global licensing of theproduct to industry partner(s) who would either alone or in collaboration withDelSiTech take the product to the markets. The Company revenues consist of licensing fees, project-related milestone payments and royalty income after the product has been launched.
Interested to hear more about business opportunities that DelSiTech can offer? Please contact us for a confidential discussion here.